3651 results for «211»
3651 results
Transcatheter solutions in young and congenital heart disease patients
17 Nov 2025 – From PCR London Valves 2025
This session focuses on transcatheter solutions tailored for young and congenital heart disease patients, featuring challenging edge-to-edge repair in extracardiac Fontan physiology, systemic AV valve TEER in congenital anomalies, multidisciplinary management of repaired tetralogy of Fallot with tricuspid regurgitation, innovative TAVI in young congenital patients, and...
Pills and pumps: targeting heart failure before and after surgical and transcatheter valve interventions
18 Nov 2025 – From PCR London Valves 2025
This session examines the integrated role of heart failure therapies in the peri- and post-procedural management of patients undergoing surgical and transcatheter valve interventions. It reviews current and emerging clinical trial data, discusses identifying high-risk patients, and explores advanced modalities such as cardiac resynchronization and circulatory...
Getting to the heart of access: mastering femoral puncture and vascular closure
18 Nov 2025 – From PCR London Valves 2025
This session provides an in-depth understanding of femoral anatomy and the critical role of imaging in ensuring safe vascular access via femoral puncture. It covers the latest equipment used for vascular access and closure, highlighting haemostasis techniques and closure devices. Interactive case scenarios offer practical insights...
Featured research - Mitral valve interventions - Part 4
18 Nov 2025 – From PCR London Valves 2025
This research-focused session presents contemporary evidence and clinical outcomes related to mitral valve interventions. It includes data on transapical mitral valve-in-ring implantation from the European Tendyne registry, prognostic utility of CT-derived fatty muscle fraction in mitral TEER, and comparative outcomes between transapical TMVR and mitral TEER....
Paravalvular leak closure - Part 3
18 Nov 2025 – From PCR London Valves 2025
This session addresses the complexities of paravalvular leak closure, emphasizing resilience in procedural approaches. It covers sizing balloon techniques that enhance treatment efficacy in aortic paravalvular leaks and explores closure strategies following Ozaki procedures. Management of mitral paravalvular leaks in high-risk patients and innovative solutions for...
TAVI complications - Part 2
17 Nov 2025 – From PCR London Valves 2025
This session explores complex and uncommon complications associated with TAVI procedures, highlighting challenging clinical scenarios such as neurological complications in bicuspid valves, management of critically unstable left ventricles, and outcomes in complex valve interventions. Each topic offers valuable lessons for improving procedural safety and patient outcomes...
Featured research - TAVI - Part 14
18 Nov 2025 – From PCR London Valves 2025
This featured research session presents pivotal findings on transcatheter aortic valve implantation (TAVI), including 30-day and one-year outcomes from the VANTAGE trial, novel concepts for assessing aortic stenosis severity, and the influence of mitral annular calcification on conduction disturbances. Additional topics cover the role of clinical...
TAVI in challenging anatomies
18 Nov 2025 – From PCR London Valves 2025
This session focuses on the challenges of performing TAVI in complex anatomical settings. It covers issues such as valve compression, hypertrophic cardiomyopathy-related left ventricular responses, alternative management strategies during crises, and handling anatomical complexities like membranous septal aneurysm at the annulus and sinus of Valsalva in...
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
